Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media

Journal of Gynecologic Oncology

Volumn 23, Issue 1, 2012, Pages 5-10

  Min, Kyung Jin ^a   So, Kyeong A ^a   Lee, Jieun ^a   Hong, Hye Ri ^a   Hong, Jin Hwa ^b   Lee, Jae Kwan ^a   Kim, Ae Ree ^a  

^a Korea University College of Medicine   (South Korea)

^b School of Medicine   (South Korea)

Author keywords

Cervista HPV 16 18; Cervista HPV HR; High risk HPV; HPV 16; HPV 18; Seeplex HPV4A ACE

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CULTURE MEDIUM; CYTOPATHOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

EID: 84863263730     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2012.23.1.5     Document Type: Article

References (17)

1. Schiffman M, Kjaer SK. Chapter 2: Natural history of anoge nital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003;(31):14-9.
2. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.
3. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370:890-907.
4. Chun JY, Kim KJ, Hwang IT, Kim YJ, Lee DH, Lee IK, et al. Dual priming oligonucleotide system for the multiplex detection of respiratory viruses and SNP genotyping of CYP2C19 gene. Nucleic Acids Res 2007;35:e40.
5. Day SP, Hudson A, Mast A, Sander T, Curtis M, Olson S, et al. Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study. J Clin Virol 2009;45 Suppl 1:S63-72.
6. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26 Suppl 10:K1-16.
7. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
8. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al. Population-based study of human pa pillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-74.
9. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical pre cancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-speci fic HPV testing in clinical practice. J Natl Cancer Inst 2005; 97:1072-9.
10. Galan-Sanchez F, Rodriguez-Iglesias MA. Use of Cervista HPV HR assay for detection of human papillomavirus in samples with hybrid capture borderline negative results. APMIS 2010;118:681-4.
11. Einstein MH, Martens MG, Garcia FA, Ferris DG, Mitchell AL, Day SP, et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC- US cytology. Gynecol Oncol 2010;118:116-22.
12. Ginocchio CC, Barth D, Zhang F. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high- risk HPV DNA. J Clin Microbiol 2008;46:1641-6.
13. Hong JH, Song SH, Kim JK, Han JH, Lee JK. Comparison of the novel human papillomavirus 4 auto-capillary elect{stroke}ro phoresis test with the hybrid capture 2 assay and with the PCR HPV typing set test in the detection of high-risk HPV including HPV 16 and 18 genotypes in cervical specimens. J Korean Med Sci 2009;24:579-84.
14. Iftner T, Germ L, Swoyer R, Kjaer SK, Breugelmans JG, Munk C, et al. Study comparing human papillomavirus (HPV) real-time multiplex PCR and Hybrid Capture II INNO-LiPA v2 HPV genotyping PCR assays. J Clin Microbiol 2009;47: 2106-13.
15. Mo LZ, Monnier-Benoit S, Kantelip B, Petitjean A, Riethmuller D, Pretet JL, et al. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results. J Clin Virol 2008;41:104-10.
16. Baleriola C, Millar D, Melki J, Coulston N, Altman P, Rismanto N, et al. Comparison of a novel HPV test with the Hybrid Capture II (hcII) and a reference PCR method shows high specificity and positive predictive value for 13 high-risk human papillomavirus infections. J Clin Virol 2008;42:22-6.
17. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, et al. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol 2010;48:2779-85.